The total dosage divided by the Defined Daily Doses (DDDs) revealed a clear upward trend for nearly all small molecule targeting inhibitors targeting lung cancer, with the exception of Gefitinib, Erlotinib, and Afatinib—representatives of the earlier generations of EGFR-targeted therapies. Here, EGFR is linked to lung carcinoma.